JP6126382B2 - 腫瘍を正確に識別し、かつＰＡＮ‐ＥｒｂＢ阻害剤に対する薬物応答を予測するＰＴＥＮタンパク質発現におけるカットポイント - Google Patents

腫瘍を正確に識別し、かつＰＡＮ‐ＥｒｂＢ阻害剤に対する薬物応答を予測するＰＴＥＮタンパク質発現におけるカットポイント Download PDF

Info

Publication number
JP6126382B2
JP6126382B2 JP2012548965A JP2012548965A JP6126382B2 JP 6126382 B2 JP6126382 B2 JP 6126382B2 JP 2012548965 A JP2012548965 A JP 2012548965A JP 2012548965 A JP2012548965 A JP 2012548965A JP 6126382 B2 JP6126382 B2 JP 6126382B2
Authority
JP
Japan
Prior art keywords
pten
protein expression
cells
pten protein
score
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012548965A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013517476A5 (enExample
JP2013517476A (ja
Inventor
マリー クオウグフルイン クリスティニア
マリー クオウグフルイン クリスティニア
ベルケンブルイト アンナ
ベルケンブルイト アンナ
マーシャル フェインゴールド ジェイ
マーシャル フェインゴールド ジェイ
スティーブン ジョンストン ダニエル
スティーブン ジョンストン ダニエル
ルイス ストラフス アンドリュー
ルイス ストラフス アンドリュー
マイケル ザクハルクフク チャールズ
マイケル ザクハルクフク チャールズ
Original Assignee
ワイス・エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ワイス・エルエルシー filed Critical ワイス・エルエルシー
Publication of JP2013517476A publication Critical patent/JP2013517476A/ja
Publication of JP2013517476A5 publication Critical patent/JP2013517476A5/ja
Application granted granted Critical
Publication of JP6126382B2 publication Critical patent/JP6126382B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2012548965A 2010-01-13 2011-01-04 腫瘍を正確に識別し、かつＰＡＮ‐ＥｒｂＢ阻害剤に対する薬物応答を予測するＰＴＥＮタンパク質発現におけるカットポイント Active JP6126382B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29461510P 2010-01-13 2010-01-13
US61/294,615 2010-01-13
PCT/US2011/020080 WO2011087926A1 (en) 2010-01-13 2011-01-04 A CUT-POINT IN PTEN PROTEIN EXPRESSION THAT ACCURATELY IDENTIFIES TUMORS AND IS PREDICTIVE OF DRUG RESPONSE TO A PAN-ErbB INHIBITOR

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015226299A Division JP2016053579A (ja) 2010-01-13 2015-11-19 腫瘍を正確に識別し、かつＰＡＮ‐ＥｒｂＢ阻害剤に対する薬物応答を予測するＰＴＥＮタンパク質発現におけるカットポイント

Publications (3)

Publication Number Publication Date
JP2013517476A JP2013517476A (ja) 2013-05-16
JP2013517476A5 JP2013517476A5 (enExample) 2014-02-27
JP6126382B2 true JP6126382B2 (ja) 2017-05-10

Family

ID=43569472

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012548965A Active JP6126382B2 (ja) 2010-01-13 2011-01-04 腫瘍を正確に識別し、かつＰＡＮ‐ＥｒｂＢ阻害剤に対する薬物応答を予測するＰＴＥＮタンパク質発現におけるカットポイント
JP2015226299A Pending JP2016053579A (ja) 2010-01-13 2015-11-19 腫瘍を正確に識別し、かつＰＡＮ‐ＥｒｂＢ阻害剤に対する薬物応答を予測するＰＴＥＮタンパク質発現におけるカットポイント

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015226299A Pending JP2016053579A (ja) 2010-01-13 2015-11-19 腫瘍を正確に識別し、かつＰＡＮ‐ＥｒｂＢ阻害剤に対する薬物応答を予測するＰＴＥＮタンパク質発現におけるカットポイント

Country Status (6)

Country Link
US (1) US8338456B2 (enExample)
EP (1) EP2524231B1 (enExample)
JP (2) JP6126382B2 (enExample)
CA (1) CA2787048C (enExample)
ES (1) ES2638821T3 (enExample)
WO (1) WO2011087926A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108421044A (zh) 2005-02-03 2018-08-21 综合医院公司 治疗吉非替尼耐药性癌症的方法
BRPI0618042A2 (pt) 2005-11-04 2011-08-16 Wyeth Corp usos de uma rapamicina e de uma herceptina, produto, pacote farmacêutico, e, composição farmacêutica
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CN102641270A (zh) 2008-06-17 2012-08-22 惠氏有限责任公司 含有hki-272和长春瑞滨的抗肿瘤组合
US8669273B2 (en) 2008-08-04 2014-03-11 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
IL264349B2 (en) 2009-04-06 2024-01-01 Wyeth Llc Regimen comprising neratinib for the treatment of cancer
NZ599762A (en) 2009-11-09 2014-07-25 Wyeth Llc Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
CA2843222A1 (en) * 2011-07-28 2013-01-31 Genentech, Inc. Pik3ca h1047r knock-in non-human animal breast cancer model
WO2014033367A1 (en) * 2012-08-30 2014-03-06 Turun Yliopisto Method of selecting individualized brain cancer therapy
US20200157563A1 (en) * 2017-07-18 2020-05-21 The Broad Institute, Inc. Methods of producing human cancer cell models and methods of use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004044218A2 (en) * 2002-11-05 2004-05-27 The Regents Of The University Of California Methods and materials for examining pathways associated with glioblastoma progression
US7399865B2 (en) 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
CA2566823A1 (en) * 2003-11-05 2005-05-19 Board Of Regents, The University Of Texas System Diagnostic and therapeutic methods and compositions involving pten and breast cancer
WO2006044748A2 (en) 2004-10-15 2006-04-27 Monogram Biosciences, Inc. RESPONSE PREDICTORS FOR ErbB PATHWAY-SPECIFIC DRUGS
WO2006116016A2 (en) * 2005-04-21 2006-11-02 The Regents Of The University Of California Molecular determinants of egfr kinase inhibitor response in glioblastoma
BRPI0618042A2 (pt) 2005-11-04 2011-08-16 Wyeth Corp usos de uma rapamicina e de uma herceptina, produto, pacote farmacêutico, e, composição farmacêutica
WO2007137187A2 (en) * 2006-05-18 2007-11-29 Molecular Profiling Institute, Inc. System and method for determining individualized medical intervention for a disease state
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
NZ600339A (en) * 2008-02-25 2013-12-20 Nestec Sa Drug selection for breast cancer therapy using antibody-based arrays
BRPI0911451A2 (pt) * 2008-05-25 2019-09-24 Wyeth Llc biomarcadores para eficácia medicamentosa de egfr/her/erb
CN106153918A (zh) 2008-10-14 2016-11-23 卡里斯Mpi公司 描绘肿瘤类型生物标志模式和特征集的基因靶和基因表达的蛋白靶

Also Published As

Publication number Publication date
WO2011087926A1 (en) 2011-07-21
EP2524231A1 (en) 2012-11-21
CA2787048C (en) 2021-06-22
US8338456B2 (en) 2012-12-25
ES2638821T3 (es) 2017-10-24
CA2787048A1 (en) 2011-07-21
US20120010240A1 (en) 2012-01-12
EP2524231B1 (en) 2017-06-28
JP2016053579A (ja) 2016-04-14
JP2013517476A (ja) 2013-05-16

Similar Documents

Publication Publication Date Title
Galdy et al. HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?
US8338456B2 (en) Cut-point in PTEN protein expression that accurately identifies tumors and is predictive of drug response to a pan-ErbB inhibitor
Zhu et al. UBE2T promotes autophagy via the p53/AMPK/mTOR signaling pathway in lung adenocarcinoma
Paccez et al. Dihydroartemisinin inhibits prostate cancer via JARID2/miR-7/miR-34a-dependent downregulation of Axl
Bacus et al. AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival
Gril et al. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain
Hegi et al. Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib—a phase II trial
Silini et al. Regulator of G-protein signaling 5 (RGS5) protein: a novel marker of cancer vasculature elicited and sustained by the tumor’s proangiogenic microenvironment
El-Guindy et al. Oct4 expression in gastric carcinoma: association with tumor proliferation, angiogenesis and survival
Martinho et al. HER family receptors are important theranostic biomarkers for cervical cancer: blocking glucose metabolism enhances the therapeutic effect of HER inhibitors
Umemura et al. Increased phosphorylation of Akt in triple‐negative breast cancers
Lee et al. Role of erbB3 receptors in cancer therapeutic resistance
JP4609930B2 (ja) Ｈｅｒ−２指向性治療に対する応答を予測する方法
WO2011070499A1 (en) Phosphatidylinositol-3-kinase pathway biomarkers
Chen et al. Increased expression of Id1 and Id3 promotes tumorigenicity by enhancing angiogenesis and suppressing apoptosis in small cell lung cancer
KR102067327B1 (ko) 최적의 암 치료를 위한 Her2 단백질 정량
Yong et al. Overexpression of Semaphorin-3E enhances pancreatic cancer cell growth and associates with poor patient survival
Lionello et al. The EGFR-mTOR pathway and laryngeal cancer angiogenesis
Radhakrishnan et al. Inhibition of rapamycin-induced AKT activation elicits differential antitumor response in head and neck cancers
Kitano et al. Synaptonemal complex protein 3 is associated with lymphangiogenesis in non-small cell lung cancer patients with lymph node metastasis
Rai et al. Phosphorylated EGFR (pEGFR T693) as a novel predictor of recurrence in non-functioning pituitary adenomas
MacNeil et al. New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
Ferrandina et al. Prognostic role of topoisomerase-IIα in advanced ovarian cancer patients
Rutkowski et al. Correlation of leptin receptor expression with BMI in differential grades of human meningiomas
Lu et al. RETRACTED ARTICLE: Nrdp1 inhibits growth of colorectal cancer cells by nuclear retention of p27

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131230

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131230

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20140829

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150302

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150721

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20151124

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160108

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20160318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20161130

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170407

R150 Certificate of patent or registration of utility model

Ref document number: 6126382

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250